Thiazolidinediones, a type of PPARγ agonist, are used to treat type 2 diabetes mellitus (T2DM) because its effect of promoting insulin sensitization, suggesting that PPARγ activation is beneficial to ameliorate diabetic cardiomyopathy (54). The gene discussed is PPARG; the disease is diabetic cardiomyopathy.